Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Update

<< Previous

Bullboard Posts

Next >>

Comment by Pareto8020on Apr 11, 2024 11:53am

92 Views

Post# 35983457

RE:RE:RE:RE:RE:Update

The fact SBM hasn't received a milestone payment doesn't bode well for a release anytime soon.

If they had received a milestone I'm sure the CEO would be yelling it from the rooftops and probably spending it immediately.

The contract was announced officially two years ago but remember Allergan had the clinical trial results much earlier since they helped pay for it. So the fact it is over 2 years and no product containing a SBM compound has hit the shelves isn't an encouraging sign. Specially with a the past issues with launching a product....Obagi, Wanbang are prime examples of continuous missteps by Howie and Co,

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages